Advertisement

Pituitary

, Volume 22, Issue 1, pp 29–36 | Cite as

Evaluation of the natural course of thyroid nodules in patients with acromegaly

  • Sema Ciftci DogansenEmail author
  • Artur Salmaslioglu
  • Gulsah Yenidunya Yalin
  • Seher Tanrikulu
  • Sema Yarman
Article
  • 75 Downloads

Abstract

Purpose

To investigate the nodular thyroid disease (NTD) and the natural course of thyroid nodules in patients with acromegaly.

Methods

138 patients with acromegaly (73 F/65 M), whose initial thyroid ultrasonography performed in our university hospital, were included in this study. The frequencies of NTD, papillary thyroid cancer (PTC) and associated factors on nodule formation were investigated at initial assessment. Patients who had NTD continued to follow-up (n = 56) were re-evaluated with a ultrasonography performed after a mean 7-years follow-up period. The nodule size changes were compared with the initial data and the factors affecting nodule growth were investigated.

Results

The frequency of NTD was found 69%. Patients with NTD were older (p = 0.05), with higher baseline IGF-1%ULN (upper limit of normal) (p = 0.01). In patients with NTD, the majority had similar nodule size (45%), decreased nodule size in 30% and nodule growth in 25%. In patients with active acromegaly at last visit, nodule growth was more significant (p < 0.001). For one unit change in the IGF-1 levels, nodule growth increased by 1.01 folds and presence of active acromegaly disease was related with ninefolds increase in nodule growth. The frequency of PTC was 14% in patients with nodule growth and PTC was diagnosed 11% of all acromegalic patients.

Conclusion

Both NTD and nodule growth is more frequent in active acromegalic patients. Thyroid nodules may show dynamic changes according to the disease activity and nodule growth should be closely monitored due to the risk of malignancy in patients with active acromegaly disease.

Keywords

Acromegaly Thyroid nodule growth Natural course IGF-1 Papillary thyroid carcinoma 

Notes

Acknowledgements

The authors highly appreciate the efforts of Assistant Professor Feyza Nur Tuncer (Istanbul University Aziz Sancar Institute of Experimental Medicine, Department of Genetics) in the language editing of this paper. And also, the authors would like to thank Sakin Tekin, MD for valuable comments in the interpretation of statistical results.

Funding

This research did not receive any spesific grant from any funding agency in the public, commercial or not-for-profit sector.

Compliance with ethical standards

Conflict of interest

The authors declare that they have no conflict of interest.

Ethical approval

All procedures performed in this study involving human participants were approved by the institutional and/or national research ethics committee and complied with the 1964 Helsinki declaration and its later amendments or comparable ethical standards. The study was approved by the Ethics Committee of Istanbul University, Istanbul Faculty of Medicine.

Informed consent

Informed consent was obtained from all individual participants included in the study.

References

  1. 1.
    Katznelson L, Laws ER Jr, Melmed S, Molitch ME, Murad MH, Utz A, Wass JA, Endocrine Society (2014) Acromegaly: an endocrine society clinical practice guideline. J Clin Endocrinol Metab 99(11):3933–3951Google Scholar
  2. 2.
    Melmed S, Casanueva FF, Klibanski A, Bronstein MD, Chanson P, Lamberts SW, Strasburger CJ, Wass JA, Giustina A (2013) A consensus on the diagnosis and treatment of acromegaly complications. Pituitary 16(3):294–302Google Scholar
  3. 3.
    Reverter JL, Fajardo C, Resmini E, Salinas I, Mora M, Llatjós M, Sesmilo G, Rius F, Halperin I, Webb SM, Ricart V, Riesgo P, Mauricio D, Puig-Domingo M (2014) Benign and malignant nodular thyroid disease in acromegaly. Is a routine thyroid ultrasound evaluation advisable? PLoS ONE 9(8):e104174Google Scholar
  4. 4.
    Wolinski K, Czarnywojtek A, Ruchala M (2014) Risk of thyroid nodular disease and thyroid cancer in patients with acromegaly–meta-analysis and systematic review. PLoS ONE 9(2):e88787Google Scholar
  5. 5.
    Dogan S, Atmaca A, Dagdelen S, Erbas B, Erbas T (2014) Evaluation of thyroid diseases and differentiated thyroid cancer in acromegalic patients. Endocrine 45(1):114–121Google Scholar
  6. 6.
    Uchoa HB, Lima GA, Corrêa LL, Vidal AP, Cavallieri SA, Vaisman M, Buescu A, Gadelha MR (2013) Prevalence of thyroid diseases in patients with acromegaly: experience of a Brazilian center. Arq Bras Endocrinol Metabol 57(9):685–690Google Scholar
  7. 7.
    Gasperi M, Martino E, Manetti L, Arosio M, Porretti S, Faglia G, Mariotti S, Colao AM, Lombardi G, Baldelli R, Camanni F, Liuzzi A, Acromegaly Study Group of the Italian Society of Endocrinology (2002) Prevalence of thyroid diseases in patients with acromegaly: results of an Italian multi-center study. J Endocrinol Invest 25(3):240–245Google Scholar
  8. 8.
    Woliński K, Stangierski A, Gurgul E, Bromińska B, Czarnywojtek A, Lodyga M, Ruchała M (2017) Thyroid lesions in patients with acromegaly—case- control study and update to the meta-analysis. Endokrynol Pol 68(1):2–6Google Scholar
  9. 9.
    dos Santos MC, Nascimento GC, Nascimento AG, Carvalho VC, Lopes MH, Montenegro R, Montenegro R Jr, Vilar L, Albano MF, Alves AR, Parente CV, dos Santos Faria M (2013) Thyroid cancer in patients with acromegaly: a case-control study. Pituitary 16(1):109–114Google Scholar
  10. 10.
    Tirosh A, Shimon I (2017) Complications of acromegaly: thyroid and colon. Pituitary 20(1):70–75Google Scholar
  11. 11.
    Herrmann BL, Baumann H, Janssen OE, Görges R, Schmid KW, Mann K (2004) Impact of disease activity on thyroid diseases in patients with acromegaly: basal evaluation and follow-up. Exp Clin Endocrinol Diabetes 112(5):225–230Google Scholar
  12. 12.
    Hegedüs L (2004) Clinical practice. The thyroid nodule. N Engl J Med 351(17):1764–1771Google Scholar
  13. 13.
    Burman KD, Wartofsky L (2015) Clinical practice. Thyroid nodules. N Engl J Med 373(24):2347–2356Google Scholar
  14. 14.
    Dagdelen S, Cinar N, Erbas T (2014) Increased thyroid cancer risk in acromegaly. Pituitary 17(4):299–306Google Scholar
  15. 15.
    Kaldrymidis D, Papadakis G, Tsakonas G, Kaldrymidis P, Flaskas T, Seretis A, Pantazi E, Kostoglou-Athanassiou I, Peppa M, Roussou P, Diamanti-Kandarakis E (2016) High incidence of thyroid cancer among patients with acromegaly. J BUON 21(4):989–993Google Scholar
  16. 16.
    Tita P, Ambrosio MR, Scollo C, Carta A, Gangemi P, Bondanelli M, Vigneri R, degli Uberti EC, Pezzino V (2005) High prevalence of differentiated thyroid carcinoma in acromegaly. Clin Endocrinol (Oxf) 63(2):161–167Google Scholar
  17. 17.
    Gullu BE, Celik O, Gazioglu N, Kadioglu P (2010) Thyroid cancer is the most common cancer associated with acromegaly. Pituitary 13(3):242–248Google Scholar
  18. 18.
    Terzolo M, Reimondo G, Berchialla P, Ferrante E, Malchiodi E, De Marinis L, Pivonello R, Grottoli S, Losa M, Cannavo S, Ferone D, Montini M, Bondanelli M, De Menis E, Martini C, Puxeddu E, Velardo A, Peri A, Faustini-Fustini M, Tita P, Pigliaru F, Peraga G, Borretta G, Scaroni C, Bazzoni N, Bianchi A, Berton A, Serban AL, Baldelli R, Fatti LM, Colao A, Arosio M, Italian Study Group of Acromegaly (2017) Acromegaly is associated with increased cancer risk: survey in Italy. Endocr Relat Cancer 24(9):495–504Google Scholar
  19. 19.
    Knudsen N, Perrild H, Christiansen E, Rasmussen S, Dige-Petersen H, Jorgensen T (2000) Thyroid structure and size and two-year follow-up of solitary cold thyroid nodules in an unselected population with borderline iodine deficiency. Eur J Endocrinol 142:224–230Google Scholar
  20. 20.
    Brander AE, Viikinkoski VP, Nickels JI, Kivisaari LM (2000) Importance of thyroid abnormalities detected at US screening: a 5-year follow-up. Radiology 215:801–806Google Scholar
  21. 21.
    Rago T, Chiovato L, Aghini-Lombardi F, Grasso L, Pinchera A, Vitti P (2001) Non-palpable thyroid nodules in a borderline iodine-sufficient area: detection by ultrasonography and follow-up. J Endocrinol Invest 24:770–776Google Scholar
  22. 22.
    Quadbeck B, Pruellage J, Roggenbuck U, Hirche H, Janssen OE, Mann K, Hoermann R (2002) Long-term follow-up of thyroid nodule growth. Exp Clin Endocrinol Diab 110:348–354Google Scholar
  23. 23.
    Alexander EK, Hurwitz S, Heering JP, Benson CB, Frates MC, Doubilet PM, Cibas ES, Larsen PR, Marqusee E (2003) Natural history of benign solid and cystic thyroid nodules. Ann Intern Med 138:315–318Google Scholar
  24. 24.
    Erdogan MF, Gursoy A, Erdogan G (2006) Natural course of benign thyroid nodules in a moderately iodine-deficient area. Clin Endocrinol (Oxf) 65(6):767–771Google Scholar
  25. 25.
    Lim DJ, Kim JY, Baek KH, Kim MK, Park WC, Lee JM, Kang MI, Cha BY (2013) Natural course of cytologically benign thyroid nodules: observation of ultrasonographic changes. Endocrinol Metab (Seoul) 28:110–118Google Scholar
  26. 26.
    Kim SY, Han KH, Moon HJ, Kwak JY, Chung WY, Kim EK (2014) Thyroid nodules with benign findings at cytologic examination: results of long-term follow-up with US. Radiology 271(1):272–281Google Scholar
  27. 27.
    Durante C, Costante G, Lucisano G, Bruno R, Meringolo D, Paciaroni A, Puxeddu E, Torlontano M, Tumino S, Attard M, Lamartina L, Nicolucci A, Filetti S (2015) The natural history of benign thyroid nodules. JAMA 313(9):926–935Google Scholar
  28. 28.
    Ajmal S, Rapoport S, Ramirez Batlle H, Mazzaglia PJ (2015) The natural history of the benign thyroid nodule: what is the appropriate follow-up strategy? J Am Coll Surg 220(6):987–992Google Scholar
  29. 29.
    Haugen BR, Alexander EK, Bible KC, Doherty GM, Mandel SJ, Nikiforov YE, Pacini F, Randolph GW, Sawka AM, Schlumberger M, Schuff KG, Sherman SI, Sosa JA, Steward DL, Tuttle RM, Wartofsky L (2016) 2015 American Thyroid Association Management Guidelines for adult patients with thyroid nodules and differentiated thyroid cancer: The American Thyroid Association guidelines task force on thyroid nodules and differentiated thyroid cancer. Thyroid 26(1):1–133Google Scholar
  30. 30.
    Cheung NW, Boyages SC (1997) The thyroid gland in acromegaly: an ultrasonographic study. Clin Endocrinol (Oxf) 46(5):545–549Google Scholar
  31. 31.
    Cannavò S, Squadrito S, Finocchiaro MD, Curtò L, Almoto B, Vieni A, Trimarchi F (2000) Goiter and impairment of thyroid function in acromegalic patients: basal evaluation and follow-up. Horm Metab Res 32(5):190–195Google Scholar
  32. 32.
    Knudsen N, Bols B, Bulow I, Jorgensen T, Perrild H, Ovesen L, Laurberg P (1999) Validation of ultrasonography of the thyroid gland for epidemiological purposes. Thyroid 9(11):1069–1074Google Scholar
  33. 33.
    Cibas ES, Ali SZ (2009) The Bethesda system for reporting thyroid cytopathology. Thyroid 19(11):1159–1165Google Scholar
  34. 34.
    Standarts of Medical Care in in Diabetes. American Diabetes Association (2016) Classification and diagnosis of diabetes mellitus. Diabetes Care 39:S13–S23Google Scholar
  35. 35.
    Ascaso JF, Pardo S, Real JT, Lorente RI, Priego A, Carmena R (2003) Diagnosing insulin resistance by simple quantitative methods in subjects with normal glucose metabolism. Diabetes Care 26(12):3320–3325Google Scholar
  36. 36.
    Braga M, Cavalcanti TC, Collaço LM, Graf H (2001) Efficacy of ultrasound-guided fine-needle aspiration biopsy in the diagnosis of complex thyroid nodules. J Clin Endocrinol Metab 86:4089–4091Google Scholar
  37. 37.
    Türkiye Endokrinoloji ve Metabolizma Derneği. Tiroid hastalıkları tanı ve tedavi kılavuzu. Ankara-Türkiye. Türkiye Klinikleri, 2017, pp 143–155Google Scholar
  38. 38.
    Kimura T, Van Keymeulen A, Golstein J, Fusco A, Dumont JE, Roger PP (2001) Regulation of thyroid cell proliferation by tsh and other factors: a critical evaluation of in vitro models. Endocr Rev 22(5):631–656Google Scholar
  39. 39.
    Yashiro T, Ohba Y, Murakami H, Obara T, Tsushima T, Fujimoto Y, Shizume K, Ito K (1989) Expression of insulin-like growth factor receptors in primary human thyroid neoplasms. Acta Endocrinol 121:112–120Google Scholar
  40. 40.
    Liu YJ, Qiang W, Shi J, Lv SQ, Ji MJ, Shi BY (2013) Expression and significance of IGF-1 and IGF-1R in thyroid nodules. Endocrine 44(1):158–164Google Scholar
  41. 41.
    Dauksiene D, Petkeviciene J, Klumbiene J, Verkauskiene R, Vainikonyte-Kristapone J, Seibokaite A, Ceponis J, Sidlauskas V, Daugintyte-Petrusiene L, Norkus A, Zilaitiene B (2017) Factors associated with the prevalence of thyroid nodules and goiter in middle-aged euthyroid subjects.Int J Endocrinol 2017:8401518Google Scholar
  42. 42.
    Wuster C, Steger G, Schmelzle A, Gottswinter J, Minne HW, Ziegler R (1991) Increased incidence of euthyroid and hyperthyroid goiters independently of thyrotropin in patients with acromegaly. Horm Metab Res 23:131–134Google Scholar
  43. 43.
    Anil C, Akkurt A, Ayturk S, Kut A, Gursoy A (2013) Impaired glucose metabolism is a risk factor for increased thyroid volume and nodule prevalence in a mild-to-moderate iodine deficient area. Metabolism 62(7):970–975Google Scholar
  44. 44.
    Yasar HY, Ertuğrul O, Ertuğrul B, Ertuğrul D, Sahin M (2011) Insulin resistance in nodular thyroid disease. Endocr Res 36(4):167–174Google Scholar
  45. 45.
    Yalcin MM, Yesil S, Akinci B, Bayraktar F, Cömlekci A, Unal S, Gulcu A, Eraslan S, Canda T (2018) Cytologic comparison between growing and non-growing benign thyroid nodules evaluated using two different growth criteria. Turk J Endocrinol Metab 22:16–20Google Scholar
  46. 46.
    Angell TE, Vyas CM, Medici M, Wang Z, Barletta JA, Benson CB, Cibas ES, Cho NL, Doherty GM, Doubilet PM, Frates MC, Gawande AA, Heller HT, Kim MI, Krane JF, Marqusee E, Moore FD Jr, Nehs MA, Zavacki AM, Larsen PR, Alexander EK (2017) Differantial growth rates of benign vs. malign thyroid nodules. J Clin Endocrinol Metab 102:4642–4647Google Scholar
  47. 47.
    Rosário PW, Calsolari MR (2015) What is the best criterion for repetition of fine-needle aspiration in thyroid nodules with initially benign cytology? Thyroid 25:1115–1120Google Scholar
  48. 48.
    Kim HK, Lee JS, Park MH, Cho JS, Yoon JH, Kim SJ, Kang HC (2014) Tumorigenesis of papillary thyroid cancer is not BRAF-dependent in patients with acromegaly. PLoS ONE 9:e110241Google Scholar

Copyright information

© Springer Science+Business Media, LLC, part of Springer Nature 2018

Authors and Affiliations

  • Sema Ciftci Dogansen
    • 1
    Email author
  • Artur Salmaslioglu
    • 2
  • Gulsah Yenidunya Yalin
    • 1
  • Seher Tanrikulu
    • 1
    • 1
  • Sema Yarman
    • 1
  1. 1.Division of Endocrinology and Metabolism, Department of Internal Medicine, Istanbul Faculty of MedicineIstanbul UniversityIstanbulTurkey
  2. 2.Department of Radiology, Istanbul Faculty of MedicineIstanbul UniversityIstanbulTurkey

Personalised recommendations